DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives

Cholangiocarcinoma (CCA) is a poorly treatable type of cancer and its incidence is dramatically increasing. The lack of understanding of the biology of this tumor has slowed down the identification of novel targets and the development of effective treatments. Based on next generation sequencing prof...

Descripción completa

Detalles Bibliográficos
Autores principales: Gönül Geyik, Öykü, Anichini, Giulia, Ulukaya, Engin, Marra, Fabio, Raggi, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101358/
https://www.ncbi.nlm.nih.gov/pubmed/35563769
http://dx.doi.org/10.3390/cells11091463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101358/
https://www.ncbi.nlm.nih.gov/pubmed/35563769
http://dx.doi.org/10.3390/cells11091463

Ejemplares similares